Category: Uncategorized

Albus Health featured in The Pharma Navigator’s latest coverage on the future of clinical trial measurement. In the piece, CEO Mikesh Udani highlights how Albus Health’s passive, non‑contact respiratory monitoring technology is helping the industry move beyond burdensome, manual data collection toward richer, more continuous, patient‑centric insights.

His perspective underscores a growing shift across life sciences: measuring what truly matters to patients while reducing friction in trial participation. You can listen to, and read the article here.

What to expect from 2026? We asked some of our journalist friends working in life sciences and healthtech. Here are answers from BioCentury, Clarivate, In Vivo, Scrip, Nature Biotech, Labiotech, Medtech Insight GlobalData, BioPharm International and Advancing RNA. We’ve included links to their relevant articles.

Please click here to read more...

AAVantgarde Bio, a clinical-stage,biotechnology company pioneering therapies for inherited retinal diseases (IRDs) has successfully closed a $141 million Series B financing round.

“This investment is a strong endorsement of our team, our science, and two clinical IRD programs,” said Dr. Natalia Misciattelli, CEO of AAVantgarde. “Both programs address the root genetic causes of devastating conditions and offer hope of improvement to patients and families living with progressive vision loss”

Please click here to read more

Please click here to read more

team of scientists from KTH Royal Institute of Technology and Karolinska Institutet has reported the development and characterization of a new class of small non-immunoglobulin affibody proteins that bind to the highly glycosylated human carcinoembryonic antigen-related adhesion molecule 5 (CEACAM5, CEA) with high affinity.

Please click here to subscribe and read the full story

Blind patients can read and recognise faces again with a “revolutionary” bionic chip, signalling a “new era” for artificial vision. The implant is an ultra-thin wireless microchip, measuring 2mm by 2mm, which is inserted under the retina and links to a video-camera fitted on a pair of augmented-reality glasses. Dozens of patients who lost their eyesight through age-related macular degeneration (AMD) were fitted with the device on a trial including Moorfields Hospital in London, with more than 80 per cent seeing major improvements.

About 600,000 people in the UK suffer from AMD, a number that is expected to increase with an ageing population, but there is currently no cure and the condition can be managed only with injections to slow the damage.

The device works with a video camera recording the scene in front of the patient, then AI is used to convert the information to an infrared signal that is beamed to the implant.

The implant stimulates undamaged inner retinal neurons, so they can transmit the signal to the brain, through the optic nerve, where it is interpreted as vision.

Please click here to read more...

Biotechnology company Neumirna Therapeutics has announced its partnership with CDMO company ten23 health to advance treatments for epilepsy and other neurological diseases. 

The companies will collaborate to advance NMT.001, a microRNA–targeting antisense oligonucleotide (ASO) designed to treat drug-resistant epilepsy, towards clinical development. The goal is to bring the therapy into clinical trials, combining ten23’s formulation and manufacturing expertise with Neumirna’s RNA innovation.

Please click here to read the full story

CPHI Frankfurt 2025:
New Trends Deliver Promise in OSDs from Core to Coating to Functional Packaging.

Click here to watch the video

Switzerland roots its foundations in life sciences collaboration

Switzerland hopes to establish its position as Europe's biotech partnership hub, attracting $3.1 billion in life sciences investment.

Click here to read more...